Table 3.
Sensitivity analysis of LTBI rate
| LTBI rate |
Strategy | Cost (US$ 2014) |
Effectiveness (QALY) |
Incremental cost (US$) |
Incremental effectiveness (QALY) |
ICER (US$/QALY) |
|---|---|---|---|---|---|---|
| 0·13 | No screening | 106·9 | 0·86 278 | 0·0 | 0·00 000 | 0·0 |
| 0·13 | QFT | 292·6 | 4·37 178 | 185·7 | 3·50 900 | 52·9 |
| 0·13 | T-SPOT | 304·7 | 4·37 144 | 12·1 | −0·00 034 | Dominated |
| 0·13 | TST/QFT | 420·0 | 4·37 260 | 127·3 | 0·00 082 | 156 009·1 |
| 0·13 | TST/T-SPOT | 426·7 | 4·37 238 | 6·7 | −0·00 021 | Dominated |
| 0·13 | TST | 615·3 | 4·36 761 | 195·3 | −0·00 499 | Dominated |
| 0·13 | CXR | 6683·3 | 4·37 560 | 6263·3 | 0·00 300 | 2 086 461·0 |
| 0·226 | No screening | 110·7 | 0·99 315 | 0·0 | 0·00 000 | 0·0 |
| 0·226 | QFT | 354·4 | 4·36 912 | 243·7 | 3·37 597 | 72·2 |
| 0·226 | T-SPOT | 369·4 | 4·36 863 | 15·0 | −0·00 049 | Dominated |
| 0·226 | TST/QFT | 474·4 | 4·37 057 | 120·0 | 0·00 145 | 82 906·6 |
| 0·226 | TST/T-SPOT | 483·6 | 4·37 023 | 9·3 | −0·00 034 | Dominated |
| 0·226 | TST | 644·0 | 4·36 567 | 169·7 | −0·00 490 | Dominated |
| 0·226 | CXR | 6683·3 | 4·37 571 | 6208·9 | 0·00 514 | 1 208 423·0 |
| 0·322 | No screening | 127·3 | 1·41 375 | 0·0 | 0·00 000 | 0·0 |
| 0·322 | QFT | 416·1 | 4·36 646 | 288·8 | 2·95 270 | 97·8 |
| 0·322 | T-SPOT | 434·1 | 4·36 582 | 18·0 | −0·00 064 | Dominated |
| 0·322 | TST/QFT | 528·8 | 4·36 854 | 112·7 | 0·00 208 | 54 208·0 |
| 0·322 | TST/T-SPOT | 540·6 | 4·36 808 | 11·9 | −0·00 046 | Dominated |
| 0·322 | TST | 672·8 | 4·36 374 | 144·0 | −0·00 480 | Dominated |
| 0·322 | CXR | 6683·3 | 4·37 581 | 6154·5 | 0·00 727 | 846 076·9 |
| 0·418 | No screening | 143·8 | 1·83 436 | 0·0 | 0·00 000 | 0·0 |
| 0·418 | QFT | 477·8 | 4·36 380 | 333·9 | 2·52 944 | 132·0 |
| 0·418 | T-SPOT | 498·8 | 4·36 300 | 21·0 | −0·00 079 | Dominated |
| 0·418 | TST/QFT | 583·2 | 4·36 651 | 105·4 | 0·00 271 | 38 880·5 |
| 0·418 | TST/T-SPOT | 597·6 | 4·36 593 | 14·4 | −0·00 058 | Dominated |
| 0·418 | TST | 701·5 | 4·36 180 | 118·4 | −0·00 471 | Dominated |
| 0·418 | CXR | 6683·3 | 4·37 592 | 6100·1 | 0·00 941 | 648 236·1 |
| 0·514 | No screening | 160·4 | 2·25 497 | 0·0 | 0·00 000 | 0·0 |
| 0·514 | QFT | 539·5 | 4·36 114 | 379·1 | 2·10 617 | 180·0 |
| 0·514 | T-SPOT | 563·5 | 4·36 019 | 24·0 | −0·00 095 | Dominated |
| 0·514 | TST/QFT | 637·6 | 4·36 448 | 98·1 | 0·00 334 | 29 345·1 |
| 0·514 | TST/T-SPOT | 654·6 | 4·36 377 | 17·0 | −0·00 070 | Dominated |
| 0·514 | TST | 730·3 | 4·35 986 | 92·7 | −0·00 461 | Dominated |
| 0·514 | CXR | 6683·3 | 4·37 602 | 6045·7 | 0·01 155 | 523 598·1 |
| 0·61 | No screening | 177·0 | 2·67 558 | 0·0 | 0·00 000 | 0·0 |
| 0·61 | QFT | 601·2 | 4·35 847 | 424·2 | 1·68 290 | 252·1 |
| 0·61 | T-SPOT | 628·2 | 4·35 738 | 26·9 | −0·00 110 | Dominated |
| 0·61 | TST/QFT | 692·0 | 4·36 245 | 90·8 | 0·00 397 | 22 840·3 |
| 0·61 | TST/T-SPOT | 711·6 | 4·36 162 | 19·6 | −0·00 083 | Dominated |
| 0·61 | TST | 759·0 | 4·35 793 | 67·1 | −0·00 452 | Dominated |
| 0·61 | CXR | 6683·3 | 4·37 613 | 5991·3 | 0·01 368 | 437 877·4 |
CXR, Chest X-ray examination; ICER, incremental cost-effectiveness ratio; LTBI, latent tuberculosis infection; QALY, quality-adjusted life-year; QFT, QuantiFERON®-TB Gold In-Tube; T-SPOT, T-SPOT®.TB; TST, tuberculin skin test.